Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, orthopedists, and primary care physicians primarily in the United States. The company markets Testim, a topical 1% testosterone gel for the treatment of hypogonadism. Its product pipeline also includes XIAFLEX, an injectable collagenase enzyme, which is in Phase III of development for the treatment of Dupuytren?s contracture; and in Phase II of development for the treatment of Peyronie?s Disease and Adhesive Capsulitis. The company?s product pipeline also comprises AA4010, which is in Phase I of development for the treatment of overactive bladder using its transmucosal film delivery system; and A Fentanyl, a pain product, which is in Phase I of development. It has agreement with Pfizer, Inc. for the development, commercialization, and supply of XIAFLEX in European and Eurasian countries. The company was founded in 1999 and is headquartered in Malvern, Pennsylvania.